RecombinantRabMAb

Recombinant Anti-C9 antibody [EPR11232-82] (ab173302)

Submit a review Submit a question References (4)
Western blot - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
  • Anti-Complement C9 antibody [EPR11232-82] (ab173302)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR11232-82] to C9
  • Suitable for: WB, IHC-P
  • Reacts with: Human

Overview

  • Product name

    Anti-C9 antibody [EPR11232-82]
    See all C9 primary antibodies

  • Description

    Rabbit monoclonal [EPR11232-82] to C9

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: IP

  • Species reactivity

    Reacts with: Human
    Does not react with: Mouse, Rat

  • Immunogen

    Recombinant fragment within Human Complement C9. The exact sequence is proprietary.
    Database link: P02748

  • Positive control

    • WB: Human serum lysates; IHC-P: human colon and spleen tissue.

  • General notes

     

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

  • Form

    Liquid

  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.

  • Storage buffer

    Preservative: 0.01% Sodium azide
    Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
  • Concentration information loading...

  • Purity

    Protein A purified

  • Clonality

    Monoclonal

  • Clone number

    EPR11232-82

  • Isotype

    IgG

  • Research areas

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab173302 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
1/1000 - 1/10000. Detects a band of approximately 72 kDa (predicted molecular weight: 63 kDa).
IHC-P
1/10000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.

For unpurified use at 1/100 - 1/200.
Notes
WB
1/1000 - 1/10000. Detects a band of approximately 72 kDa (predicted molecular weight: 63 kDa).
IHC-P
1/10000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.

For unpurified use at 1/100 - 1/200.
  • Application notes
    Is unsuitable for IP.

    • Target

    • Function

      Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.

    • Tissue specificity

      Plasma.

    • Involvement in disease

      Defects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.

    • Sequence similarities

      Belongs to the complement C6/C7/C8/C9 family.
      Contains 1 EGF-like domain.
      Contains 1 LDL-receptor class A domain.
      Contains 1 MACPF domain.
      Contains 1 TSP type-1 domain.

    • Post-translational
      modifications

      Thrombin cleaves factor C9 to produce C9a and C9b.
      Phosphorylation sites are present in the extracelllular medium.

    • Cellular localization

      Secreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore.
    • Information by UniProt

    • Database links

      • Alternative names

        • ARMD15 antibody
        • C9 antibody
        • C9 deficiency antibody
        • C9 deficiency with dermatomyositis antibody
        • C9D antibody
        • CO9_HUMAN antibody
        • Complement component 9 antibody
        • Complement component 9 deficiency antibody
        • Complement component C9 antibody
        • Complement component C9b antibody
        see all

      Images

      • Western blot - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Western blot - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Anti-C9 antibody [EPR11232-82] (ab173302) at 1/10000 dilution (Purified) + Human serum lysates at 15 µg

        Secondary
        Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

        Predicted band size: 63 kDa
        Observed band size: 60-70 kDa why is the actual band size different from the predicted?



        The molecular weight observed is consistent with what has been described in PMID: 29767720

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)

        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human colon tissue sections labeling Complement C9 with purified ab173302 at 1/10,000 dilution (0.07 µg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)

        Immunohistochemical analysis of paraffin embedded Human colon tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.

      • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)

        Immunohistochemical analysis of paraffin embedded Human spleen tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.

      • Anti-Complement C9 antibody [EPR11232-82] (ab173302)
        Anti-Complement C9 antibody [EPR11232-82] (ab173302)

      References (4)

      Publishing research using ab173302? Please let us know so that we can cite the reference in this datasheet.

      ab173302 has been referenced in 4 publications.

      • D'Agnillo F  et al. Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis. Am J Pathol 190:2095-2110 (2020). PubMed: 32598882
      • Deleon-Pennell KY  et al. Glycoproteomic Profiling Provides Candidate Myocardial Infarction Predictors of Later Progression to Heart Failure. ACS Omega 4:1272-1280 (2019). PubMed: 30729226
      • Zhao P  et al. The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer. BMC Cancer 19:201 (2019). PubMed: 30841875
      • Tougan T  et al. Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Sci Rep 8:5052 (2018). PubMed: 29567995

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      There are currently no Customer reviews or Questions for ab173302.
      Please use the links above to contact us or submit feedback about this product.

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com